Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02378220 · ClinicalTrials.gov registry record · NA
Pharmacogenetic Testing Among Home Health Patients
A NA study, sponsored by Genelex Corporation.
- Completed
- Registry status
- NA
- Development phase
- 110
- Enrollment target
NCT02378220: Completed NA study, sponsored by Genelex Corporation.
NCT02378220 is a NA study that has completed, run by Genelex Corporation. The registered enrollment target is 110 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02378220, a NA study, has completed, sponsored by Genelex Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 110 participants
- Enrollment target
Study Summary
Patients meeting eligibility criteria will be randomized into two groups, one receiving pharmacogenetic testing and the other not receiving pharmacogenetic testing. In this open-label trial, a pharmacist will make medication therapy recommendations using YouScript® Personalized Prescribing System for patients who receive genetic testing and standard drug information resources per usual for patients who do not undergo pharmacogenetic testing.
Primary Outcome
The primary outcomes included the number of re-hospitalizations at 30 and 60 days.
Interventions
- GENETIC Pharmacogenetic testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2015-03 |
| Est. Completion | 2016-03 |
| Phase | NA |
What the finished NCT02378220 record still lists
NCT02378220 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which Pharmacogenetic testing is the first listed.
NCT02378220 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02378220 about?
NCT02378220 is a clinical study titled "Pharmacogenetic Testing Among Home Health Patients". Patients meeting eligibility criteria will be randomized into two groups, one receiving pharmacogenetic testing and the other not receiving pharmacogenetic testing. In this open-label trial, a pharmacist will make medication therapy recommendations using YouScript® Personalized Prescribing System fo...
What is the current status of trial NCT02378220?
This trial is currently completed. It is a NA study. The enrollment target is 110 participants. The study started on 2015-03. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02378220?
The interventions under investigation include: Pharmacogenetic testing (GENETIC).
Who is sponsoring clinical trial NCT02378220?
This trial is sponsored by Genelex Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02378220's enrollment target sits among peer trials
110 816th of 2000 higher than 1,176 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia